Computational evaluation of chromone–tetrazole hybrids as noncovalent inhibitors of SARS-CoV-2 Mpro
Résumé
Emerging SARS-CoV-2 variants continue to demand orally tractable, non-covalent inhibitors of the conserved main protease (Mpro). Here, chromone-phenyl-tetrazole hybrids were prioritized using a multiscale computational strategy that connects drug-likeness, binding stability, free-energy ranking, conformational behavior, and quantum-level electronic features. The series showed favorable oral drug-like profiles and low-to-moderate predicted acute toxicity. Among the stable Mpro complexes, M2 displayed the strongest computed affinity (MM/GBSA ΔGbind = -38.8 kcal·mol ⁻ ¹), driven mainly by dispersion with limited desolvation cost, whereas M4 showed the most direct catalytic-dyad engagement through His41/Cys145-supported anchoring. DFT analysis rationalized these complementary profiles: M2 and M4 exhibited narrower HOMO-LUMO gaps (4.00 eV) and higher electronic softness, while ELF/NCI maps revealed heteroatom-centered electron reservoirs and weak intramolecular preorganization. The derived pharmacophore consists of a planar chromone π-platform bearing a carbonyl/phenolic acceptor-donor edge, a para-phenyl spacer for conjugation and hydrophobic occupancy, and a methoxy-tetrazole polar/π-rich head for Glu166/Phe140/His163 anchoring. Overall, M2 and M4 emerge as complementary lead chemotypes for experimental validation and structure-guided optimization against Mpro.
Citer ce document
Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)
Accès au document
Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter
Voir l'article sur le site de la revueLicence et provenance
Licence : CC BY
Notice moissonnée depuis OpenAlex le 16/11/2026. Le document reste hébergé par sa source.
Voir le document à la source →